Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4904367 | 0.85 | KMT2A (0.48) | ALDH1A1KDM4EHPGDHSD17B10RECQL | |
| SCHEMBL14399296 | 0.83 | ALDH1A1 (0.44) | ALDH1A1KDM4EHPGDHSD17B10RECQL | |
| SCHEMBL13229696 | 0.79 | MEN1 (0.40) | ALDH1A1KDM4EMAPTMEN1KMT2A | |
| SCHEMBL10474018 | 0.79 | TP53 (0.50) | ALDH1A1KDM4ESMN1; SMN2MAPTPKM | |
| SCHEMBL6368861 | 0.78 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDHSD17B10RECQL | |
| SCHEMBL6289493 | 0.78 | LMNA (0.46) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL9837120 | 0.78 | KDM4E (0.44) | ALDH1A1KDM4EHPGDHSD17B10RECQL | |
| SCHEMBL30916871 | 0.78 | ALDH1A1 (0.47) | ALDH1A1KDM4EHPGDHSD17B10RECQL | |
| SCHEMBL4543435 | 0.77 | GPR35 (0.41) | ALDH1A1KDM4EHPGDRECQLMAPT | |
| SCHEMBL9182646 | 0.76 | MEN1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7010880-A | — | — | None | — | — | JP | disclosed |
| EP-2170901-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20140235668-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VPI | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235668-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VPI | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235668-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VPI | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-08-21 | — | — | US | disclosed |
| US-8710075-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-04-29 | — | — | US | disclosed |
| US-8604030-B2 | Fused piperidine compound and pharmaceutical containing same | KOWA COMPANY, LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| EP-2637660-A1 | FATTY ACID SYNTHASE INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-09-18 | — | — | EP | disclosed |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-09-12 | — | — | US | disclosed |
| US-20130231364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-09-05 | — | — | US | disclosed |
| US-20020143030-A1 | TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS | R.T. ALAMO VENTURES I, L.L.C, | 2002-10-03 | — | — | US | disclosed |
| US-20020143031-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | R.T. ALAMO VENTURES I, L.L.C. | 2002-10-03 | — | — | US | disclosed |
| US-6458804-B1 | UTILIZATION OF PHARMACEUTICAL COMPOSITIONS COMPRISING QUINOLINONES (AND DERIVATIVES THEREOF) IN PATIENTS WITH SYMPTOMS OF A CENTRAL NERVOUS SYSTEM DISORDER WHO ARE OTHERWISE FREE OF CARDIAC DISEASE AND/OR WHO HAVE NOT BEEN | R.T. ALAMO VENTURESI, LLC | 2002-10-01 | — | — | US | disclosed |
| US-6451813-B1 | Treatment of gastroparesis in certain patient groups | R. T. ALAMO VENTURES I, LLC | 2002-09-17 | — | — | US | disclosed |
| US-5468750-A | Antiinflammatory agents and autoimmune diseases | ELF SANOFI (FR) | 1995-11-21 | — | — | US | disclosed |
| JP-H0710880-A | PRODUCTION OF THIENO(2,3-B)PYRIMIDINE DERIVATIVE | MITSUBISHI CHEM CORP | 1995-01-13 | — | — | JP | disclosed |
| US-5360799-A | Free radical inhibitors | ELF SANOFI (FR) | 1994-11-01 | — | — | US | disclosed |
| EP-0269295-B1 | THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1991-06-26 | — | — | EP | disclosed |
| US-4877793-A | CARDIOVASCULAR DISORDERS | THE BOOTS COMPANY, PLC (GB) | 1989-10-31 | — | — | US | disclosed |
| EP-0269295-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235668-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VPI | CFTR, ABCB1, ABCC1 | ALDH1A1 4065/4885KDM4E 3850/4885HPGD 1808/4885 |
| US-20020143031-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | TNNT2, TNNI3, NOS3 | ALDH1A1 392/4885KDM4E 871/4885HPGD 204/4885 |
| US-20020143030-A1 | TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS | FABP6, SLC10A2, FABP2 | ALDH1A1 1961/4885KDM4E 4676/4885HPGD 25/4885 |
| US-20130237535-A1 | FATTY ACID SYNTHASE INHIBITORS | FASN, FADS1, FADS2 | ALDH1A1 199/4885KDM4E 2007/4885HPGD 487/4885 |
| US-20130231364-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC1 | ALDH1A1 3001/4885KDM4E 4285/4885HPGD 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.